Swiss food giant Nestlé will launch a takeover bid to buy American allergy specialist Aimmune Therapeutics, valued at $ 2.6 billion (€ 2.1 billion), he announced. Monday.
Read also: Purina, Nestlé's nugget, impervious to the crisis
Nestlé, which already owns a 25.6% stake in the company, will offer its shareholders $ 34.50 per share, which represents a premium of 174% over Aimmune's closing price on August 28, 2020 , he said in a statement.